Is Structure Therapeutics Stock a Good Investment?
Structure Therapeutics Investment Advice | GPCR |
- Examine Structure Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Structure Therapeutics' leadership team and their track record. Good management can help Structure Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Structure Therapeutics' business and its evolving consumer preferences.
- Compare Structure Therapeutics' performance and market position to its competitors. Analyze how Structure Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Structure Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Structure Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Structure Therapeutics American stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Structure Therapeutics American is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Structure Therapeutics Stock
Researching Structure Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.34. Some equities with similar Price to Book (P/B) outperform the market in the long run. Structure Therapeutics recorded a loss per share of 2.16. The entity had not issued any dividends in recent years.
To determine if Structure Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Structure Therapeutics' research are outlined below:
| Structure Therapeutics generated a negative expected return over the last 90 days | |
| Structure Therapeutics has high historical volatility and very poor performance | |
| Structure Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (89.62 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Structure Therapeutics generates negative cash flow from operations | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist |
Structure Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Structure Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Structure Therapeutics American. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Structure Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Structure Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Structure Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -0.225 | -0.18 | 0.045 | 20 | ||
2023-05-11 | 2023-03-31 | -0.41 | -0.25 | 0.16 | 39 | ||
2023-08-10 | 2023-06-30 | -0.28 | -0.6 | -0.32 | 114 | ||
2023-03-31 | 2022-12-31 | -0.82 | -1.14 | -0.32 | 39 | ||
2024-03-08 | 2023-12-31 | -0.21 | -0.5316 | -0.3216 | 153 | ||
2023-11-14 | 2023-09-30 | -0.29 | -0.62 | -0.33 | 113 |
Structure Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.21 B.Market Cap |
|
Structure Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.20) | (0.21) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.23) | (0.22) |
Determining Structure Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Structure Therapeutics is a good buy. For example, gross profit margin measures Structure Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Structure Therapeutics' profitability and make more informed investment decisions.
Evaluate Structure Therapeutics' management efficiency
Structure Therapeutics has return on total asset (ROA) of (0.1546) % which means that it has lost $0.1546 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2029) %, meaning that it created substantial loss on money invested by shareholders. Structure Therapeutics' management efficiency ratios could be used to measure how well Structure Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/26/2025, Return On Tangible Assets is likely to drop to -0.18. In addition to that, Return On Capital Employed is likely to drop to -0.21. At this time, Structure Therapeutics' Total Assets are relatively stable compared to the past year. As of 02/26/2025, Non Current Assets Total is likely to grow to about 10.2 M, while Non Currrent Assets Other are likely to drop slightly above 49.2 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.92 | 0.97 | |
| Tangible Book Value Per Share | 0.92 | 0.97 | |
| Enterprise Value Over EBITDA | (156.72) | (164.56) | |
| Price Book Value Ratio | 11.90 | 12.49 | |
| Enterprise Value Multiple | (51.51) | (54.09) | |
| Price Fair Value | 11.90 | 12.49 |
Structure Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta (2.91) |
Basic technical analysis of Structure Stock
As of the 26th of February, Structure Therapeutics has the Risk Adjusted Performance of (0.07), variance of 21.23, and Coefficient Of Variation of (901.25). Structure Therapeutics technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. Please validate Structure Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Structure Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 21.09 per share. Given that Structure Therapeutics has information ratio of (0.11), we advise you to double-check Structure Therapeutics American's current market performance to make sure the company can sustain itself at a future point.Structure Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Structure Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Structure Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Structure Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Structure Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Structure Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.34) | |||
| Mean Deviation | 3.31 | |||
| Coefficient Of Variation | (901.25) | |||
| Standard Deviation | 4.61 | |||
| Variance | 21.23 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.35) | |||
| Maximum Drawdown | 22.52 | |||
| Value At Risk | (8.73) | |||
| Potential Upside | 6.75 | |||
| Skewness | (0.42) | |||
| Kurtosis | 0.5098 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.34) | |||
| Mean Deviation | 3.31 | |||
| Coefficient Of Variation | (901.25) | |||
| Standard Deviation | 4.61 | |||
| Variance | 21.23 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.35) | |||
| Maximum Drawdown | 22.52 | |||
| Value At Risk | (8.73) | |||
| Potential Upside | 6.75 | |||
| Skewness | (0.42) | |||
| Kurtosis | 0.5098 |
Consider Structure Therapeutics' intraday indicators
Structure Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Structure Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Structure Therapeutics Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 10th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 13th of January 2025 Other Reports | ViewVerify | |
8K | 17th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Structure Stock media impact
Far too much social signal, news, headlines, and media speculation about Structure Therapeutics that are available to investors today. That information is available publicly through Structure media outlets and privately through word of mouth or via Structure internal channels. However, regardless of the origin, that massive amount of Structure data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Structure Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Structure Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Structure Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Structure Therapeutics alpha.
Structure Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Structure Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Structure Therapeutics Historical Investor Sentiment
Investor biases related to Structure Therapeutics' public news can be used to forecast risks associated with an investment in Structure. The trend in average sentiment can be used to explain how an investor holding Structure can time the market purely based on public headlines and social activities around Structure Therapeutics American. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Structure Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Structure Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Structure Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Structure Therapeutics.
Structure Therapeutics Corporate Management
| Lani Ibarra | Senior Operations | Profile | |
| Hui Lei | Senior Chemistry | Profile | |
| Xichen Lin | Chief Officer | Profile | |
| Yingli Ma | Chief Officer | Profile | |
| Fang Zhang | Executive Biology | Profile |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.